This episode features Dr. Guru Sonpavde, GU Oncology, Phase I Director, Christopher K. Glanz Chair Bladder Cancer Research, Prof. UCF - AdventHealth Central Florida. Here, he discusses his recent NEJM paper on a Phase 3 trial tied to GU cancer and the drug combo of chemotherapy and immunotherapy improving durable complete remission rates to ~22% from ~12%, most focused on and excited about in the next 3-5 years, advice for evolving researchers, and more.

Link to paper here: https://www.nejm.org/doi/full/10.1056/NEJMoa2309863